|
1
|
Kitamura K, Hoshino T, Okabe A, Fukuyo M, Rahmutulla B, Tanaka N, Kobayashi S, Tanaka T, Shida T, Ueda M, Minamoto T, Matsubara H, Kaneda A, Ishii H, Matsushita K. The Link of mRNA and rRNA Transcription by PUF60/FIR through TFIIH/P62 as a Novel Therapeutic Target for Cancer. Int J Mol Sci 2023; 24:17341. [PMID: 38139171 PMCID: PMC10743661 DOI: 10.3390/ijms242417341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Revised: 12/05/2023] [Accepted: 12/06/2023] [Indexed: 12/24/2023] Open
Abstract
The interaction between mRNA and ribosomal RNA (rRNA) transcription in cancer remains unclear. RNAP I and II possess a common N-terminal tail (NTT), RNA polymerase subunit RPB6, which interacts with P62 of transcription factor (TF) IIH, and is a common target for the link between mRNA and rRNA transcription. The mRNAs and rRNAs affected by FUBP1-interacting repressor (FIR) were assessed via RNA sequencing and qRT-PCR analysis. An FIR, a c-myc transcriptional repressor, and its splicing form FIRΔexon2 were examined to interact with P62. Protein interaction was investigated via isothermal titration calorimetry measurements. FIR was found to contain a highly conserved region homologous to RPB6 that interacts with P62. FIRΔexon2 competed with FIR for P62 binding and coactivated transcription of mRNAs and rRNAs. Low-molecular-weight chemical compounds that bind to FIR and FIRΔexon2 were screened for cancer treatment. A low-molecular-weight chemical, BK697, which interacts with FIRΔexon2, inhibited tumor cell growth with rRNA suppression. In this study, a novel coactivation pathway for cancer-related mRNA and rRNA transcription through TFIIH/P62 by FIRΔexon2 was proposed. Direct evidence in X-ray crystallography is required in further studies to show the conformational difference between FIR and FIRΔexon2 that affects the P62-RBP6 interaction.
Collapse
Affiliation(s)
- Kouichi Kitamura
- Department of Laboratory Medicine, Chiba University Hospital, Chiba 260-8677, Japan; (K.K.); (N.T.); (S.K.)
- Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan;
| | - Tyuji Hoshino
- Department of Molecular Design, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan;
| | - Atsushi Okabe
- Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; (A.O.); (M.F.); (B.R.); (A.K.)
| | - Masaki Fukuyo
- Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; (A.O.); (M.F.); (B.R.); (A.K.)
| | - Bahityar Rahmutulla
- Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; (A.O.); (M.F.); (B.R.); (A.K.)
| | - Nobuko Tanaka
- Department of Laboratory Medicine, Chiba University Hospital, Chiba 260-8677, Japan; (K.K.); (N.T.); (S.K.)
| | - Sohei Kobayashi
- Department of Laboratory Medicine, Chiba University Hospital, Chiba 260-8677, Japan; (K.K.); (N.T.); (S.K.)
- Department of Medical Technology and Sciences, Health and Sciences, International University of Health and Welfare, Chiba 286-8686, Japan
| | - Tomoaki Tanaka
- Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan;
| | - Takashi Shida
- Research Team for Promoting Independence and Mental Health, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo 173-0015, Japan;
| | - Mashiro Ueda
- Master’s Program in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba 305-8575, Japan;
| | - Toshinari Minamoto
- Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa 920-1192, Japan;
| | - Hisahiro Matsubara
- Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan;
| | - Atsushi Kaneda
- Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; (A.O.); (M.F.); (B.R.); (A.K.)
| | - Hideshi Ishii
- Medical Data Science, Center of Medical Innovation and Translational Research (CoMIT), Osaka University, Osaka 565-0871, Japan;
| | - Kazuyuki Matsushita
- Department of Laboratory Medicine, Chiba University Hospital, Chiba 260-8677, Japan; (K.K.); (N.T.); (S.K.)
| |
Collapse
|